Pentoxifylline effect on COVID 19
Phase 2
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
- Registration Number
- CTRI/2022/01/039786
- Lead Sponsor
- Dr Subhash Gupta
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Adult male or female patients, with proven COVID-19 moderate disease with any one of respiratory rate 24- 30/min, breathlessness, SPO2 90-93% on room air will be included in the study.
Exclusion Criteria
(a)Children < 18 years of age, age >70 years
(b)Pregnancy & lactation
(c)History of GI bleeding
(d)History of Seizures, Cardiac or other vascular stents
(e)History of intracranial hemorrhage
(f)Patients with recent cerebral and/or retinal hemorrhage/ intracranial haemorrhage
(g)Pts with serum ALT/AST > 5 times the upper limit of normal
(h)In patients who have previously exhibited intolerance to this product
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method